Invezz is a place where people can find reliable, unbiased information about finance, trading, and investing – but we do not offer financial advice and users should always carry out their own research. The assets covered on this website, including stocks, cryptocurrencies, and commodities can be highly volatile and new investors often lose money. Success in the financial markets is not guaranteed, and users should never invest more than they can afford to lose. You should consider your own personal circumstances and take the time to explore all your options before making any investment. Read our risk disclaimer >
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Forma Therapeutics Holdings Inc. (NASDAQ:FMTX)
|Dividend Rate (ttm)||0.0000|
|Trading Day||Jun 18|
|Day's Range||24.64 - 26.21|
|52 Week Range||21.1 - 56.33|
Forma Therapeutics Holdings Inc. dividends
Forma Therapeutics Holdings Inc has a market cap or net worth of $1.23 billion. The enterprise value is $0.
Forma Therapeutics Holdings Inc has 47.37 million shares outstanding.
The trailing PE ratio is 0.0000 and the forward PE ratio is -8.5330. Forma Therapeutics Holdings Inc's PEG ratio is 0.0000.
Stock Price Statistics
The stock price has decreased by -0.2553%. The beta is 0.9324, so Forma Therapeutics Holdings Inc's price volatility has been lower than the market average.
In the last 12 months, Forma Therapeutics Holdings Inc had revenue of $0 and earned $0 in profits. Earnings per share was $.
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Its R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need.
Its work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit..